NurExone Biologic Inc. has been named a finalist in the Falling Walls Venture 2025, a global platform showcasing science-based start-ups. The company’s CEO, Dr. Lior Shaltiel, expressed gratitude for the opportunity to present their drug, ExoPTEN, at the Falling Walls Science Summit in Berlin. NurExone will have access to exclusive networking events as a finalist, connecting with investors, partners, and thought leaders. The company focuses on developing regenerative therapies for central nervous system injuries, with ExoPTEN showing promise in treating spinal cord and optic nerve injuries. NurExone aims to provide solutions for targeted drug delivery systems and has established a U.S. subsidiary, Exo-Top Inc. for North American operations. The winner of the Falling Walls Venture will be awarded the title ‘Science Breakthrough of the Year’ in the science start-up category.

Read more at GlobeNewswire: NurExone Biologic Finalist in Falling Walls Venture 2025